Pfizer Stock Brushes Off Forecast Cut on Analyst Upgrade
The shares of Pfizer Inc (NYSE:PFE) have reversed their premarket losses, up 4.5% at $33.57 at last glance.
Pfizer (PFE) Cuts 2023 Outlook as COVID Products' Demand Falls
Pfizer (PFE) lowers its total revenue guidance for 2023 by $9 billion as sales from its COVID products, Comirnaty vaccine and Paxlovid pill decline.
Pfizer cuts guidance on slumping COVID vaccine, treatment sales
"Pfizer (PFE) lowered its 2023 sales forecast on waning COVID vaccine demand, but analysts say cost cuts and new drug launches can drive growth. Yahoo Finance's Seana Smith reports on how low deman...
Pfizer's earnings cut was 'sort of telegraphed', says E Squared's Les Funtleyder
Les Funtleyder, E Squared Capital Management healthcare portfolio manager, joins 'Squawk Box' to discuss Pfizer cutting full-year revenue guidance by $9 billion, after the pharmaceutical giant said...
Pfizer's Sequel: Return Of The Value Stock
Pfizer is focusing on its core growth engines and strategic acquisitions, particularly in the oncology segment, to compensate for downgraded revenue projections and a concerning debt profile. The c...
Pfizer: Buy This Big Pharma Stock For Safe Income And Deep Value
Combining sustainable income and deep value is an investing strategy that can work very well over the long run. Pfizer's market-smashing dividend is comfortably covered by its adjusted diluted EPS....
Pfizer slashes outlook: Projects weak demand for Covid-19 vaccine and Paxlovid
Hosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy. Tune in Monday through Friday at 7 p.m.
Pfizer Launches $3.5 Billion Cost-Cutting Program Amid Declining Covid Vaccine Sales
The pharmaceutical company warned in January it expected revenue for its Covid vaccine and Paxlovid pill to drop sharply.
Pfizer slashes full-year earnings and revenue guidance as Covid treatment, vaccine sales slump
Pfizer said it anticipates sales of its Covid treatment Paxlovid and its vaccine will be $9 billion less than it had expected.
Pfizer warns of delayed Paxlovid commercialization and lower Covid demand
CNBC's Angelica Peebles joins 'Closing Bell: Overtime' to discuss Pfizer earnings.
Pfizer's stock sinks after company cuts outlook on lower demand for COVID products
Pfizer Inc. PFE, -2.46% shares dropped in the extended session Friday after the drug maker slashed its full-year outlook due to COVID product write offs. Pfizer shares dropped more than 7% after ho...
FDA Approves Pfizer's (PFE) Braftovi + Mektovi for Lung Cancer
Pfizer's (PFE) Braftovi + Mektovi drug combo gets label expansion for BRAF V600E-mutant non-small cell lung cancer.
New RSV protections for infants hit cost, insurance hurdles in U.S. rollout
Pfizer's maternal vaccine, Abrysvo, and Sanofi's monoclonal antibody, Beyfortus, were approved for expectant mothers and infants in the U.S. earlier this year.
U.S. FDA approves Pfizer's inflammatory bowel disease drug
Pfizer said on Friday that theU.S. Food and Drug Administration has approved its drug to treat adults with moderate-to-severe inflammatory bowel disease, ulcerative colitis.
EU regulator backs Pfizer's blood cancer therapy
The European Union medicines regulator on Friday recommended a conditional marketing authorization for U.S. drugmaker Pfizer's therapy for a type of blood cancer that is difficult to treat.
Related Companies